Cellular resistance to anthracyclines.

No abstract is available for this paper.

• Publication year

  1996

• Venue

  General Pharmacology

• Publication date

  1996-03-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/0306-3623(95)02013-6PMID 8919638
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Molecular and Clinical Advances in Anticancer Drug Resistance

  2012cited by this paper
• Preclinical investigations of drug resistance.

  1995cited by this paper
• Anthracycline antibiotics in cancer therapy. Focus on drug resistance.

  1994cited by this paper
• Cellular resistance to cancer chemotherapy.

  1994cited by this paper
• Glutathione-associated enzymes in anticancer drug resistance.

  1994cited by this paper
• Kinetics of daunorubicin transport in Ehrlich ascites tumor cells with different expression of P-glycoprotein.

  1994cited by this paper
• Biochemistry of multidrug resistance mediated by the multidrug transporter.

  1993cited by this paper
• The MRP gene associated with a non-P-glycoprotein multidrug resistance encodes a 190-kDa membrane bound glycoprotein.

  1993cited by this paper
• Clinical trials of agents that reverse multidrug resistance. A literature review

  1993cited by this paper
• Examination by laser scanning confocal fluorescence imaging microscopy of the subcellular localisation of anthracyclines in parent and multidrug resistant cell lines.

  1993cited by this paper
• Overexpression of a M(r) 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance.

  1993cited by this paper
• Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line.

  1992cited by this paper
• Energy-dependent processes involved in reduced drug accumulation in multidrug-resistant human lung cancer cell lines without P-glycoprotein expression.

  1992cited by this paper
• Multifactorial resistance to antineoplastic agents in drug-resistant P388 murine leukemia, Chinese hamster ovary, and human HeLa cells, with emphasis on the role of DNA topoisomerase II.

  1992cited by this paper
• From amplification to function: the case of the MDR1 gene.

  1992cited by this paper
• ABC transporters: from microorganisms to man.

  1992cited by this paper
• The molecular pharmacology of doxorubicin in vivo.

  1991cited by this paper
• Decreased DNA topoisomerase II in daunorubicin-resistant Ehrlich ascites tumor cells.

  1991cited by this paper
• Catalytic function of DNA topoisomerase II

  1991cited by this paper
• Characterization of adriamycin-resistant human breast cancer cells which display overexpression of a novel resistance-related membrane protein.

  1990cited by this paper
• Pharmacology of drugs that alter multidrug resistance in cancer.

  1990cited by this paper
• Photosensitized labeling of a functional multidrug transporter in living drug-resistant tumor cells.

  1990cited by this paper
• Clinical trials of agents that reverse multidrug-resistance.

  1989cited by this paper
• The biochemistry of P-glycoprotein-mediated multidrug resistance.

  1989cited by this paper
• Quantitative determination of factors contributing to doxorubicin resistance in multidrug-resistant cells.

  1989cited by this paper
• Expression of a human multidrug resistance cDNA (MDR1) in the bone marrow of transgenic mice: resistance to daunomycin-induced leukopenia

  1989cited by this paper
• Enhancement of adriamycin-induced cytotoxicity by increasing retention and inhibition of DNA repair in DOX-resistant P388 cell lines with new calcium channel blocker, DMDP.

  1989cited by this paper
• Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells.

  1986cited by this paper
• Active outward transport of daunomycin in resistant Ehrlich ascites tumor cells.

  1973cited by this paper

• Functionalizing Injectable Hydrogels with Cobalt‐Based Metallacarboranes for Targeted Delivery in Triple‐Negative Breast Cancer

  2025cites this paper
• Targeting the 3D genome by anthracyclines for chemotherapeutic effects.

  2025cites this paper
• Overcoming acquired doxorubicin resistance of ovarian carcinoma cells by verapamil-mediated promotion of DNA damage-driven cell death

  2025cites this paper
• Targeting the 3D genome by anthracyclines for chemotherapeutic effects

  2024cites this paper
• Using Poly(amidoamine) PAMAM-βCD Dendrimer for Controlled and Prolonged Delivery of Doxorubicin as Alternative System for Cancer Treatment

  2024cites this paper
• Re-Exploring the Anthracycline Chemical Space for Better Anti-Cancer Compounds

  2023cites this paper
• Application Prospects of Triphenylphosphine-Based Mitochondria-Targeted Cancer Therapy

  2023cites this paper
• Effect of siRNA-mediated silencing of p53R2 gene on sensitivity of T-ALL cellsto Daunorubicin.

  2023cites this paper
• Piperlongumine, a piper alkaloid, enhances the efficacy of doxorubicin in breast cancer: involvement of glucose import, ROS, NF-κB and lncRNAs

  2022cites this paper
• Immunotherapy in triple-negative breast cancer: Insights into tumor immune landscape and therapeutic opportunities

  2022cites this paper
• Two-Photon Photodynamic Therapy Targeting Cancers with Low Carboxylesterase 2 Activity Guided by Ratiometric Fluorescence.

  2022cites this paper
• Deciphering molecular mechanisms underlying chemoresistance in relapsed AML patients: towards precision medicine overcoming drug resistance

  2021cites this paper
• Polymeric Nanocarriers: A Transformation in Doxorubicin Therapies

  2021cites this paper
• Bruton’s Tyrosine Kinase Inhibitors Ibrutinib and Acalabrutinib Counteract Anthracycline Resistance in Cancer Cells Expressing AKR1C3

  2020cites this paper
• Acquisition of stem associated-features on metastatic osteosarcoma cells and their functional effects on mesenchymal stem cells.

  2020cites this paper
• Co-Delivery of Hispolon and Doxorubicin Liposomes Improves Efficacy Against Melanoma Cells

  2020cites this paper
• Analysis of determinants for in vitro resistance to the small molecule deubiquitinase inhibitor b-AP15

  2019cites this paper
• Photoactivatable Prodrug of Doxazolidine Targeting Exosomes.

  2019cites this paper
• Optimized synthesis, characterization and in vitro systematic evaluation of adamantane-doxorubicin prodrugs sensitive to pH in breast cancer cells

  2019cites this paper
• Inhibition of human erythrocyte glutathione S-transferase by some flavonoid derivatives

  2018cites this paper
• Synergistic Effect of Endogenous and Exogenous Aldehydes on Doxorubicin Toxicity in Yeast

  2018cites this paper
• The current understanding of mesenchymal stem cells as potential attenuators of chemotherapy‐induced toxicity

  2018cites this paper
• Daunorubicin reduces MBNL1 sequestration caused by CUG-repeat expansion and rescues cardiac dysfunctions in a Drosophila model of myotonic dystrophy

  2018cites this paper
• Experimental therapy of doxorubicin resistant human uveal melanoma with targeted cytotoxic luteinizing hormone‐releasing hormone analog (AN‐152)

  2018cites this paper
• 1. Study on the Effector Domain of MARCKS Protein as a Cell Penetrating Peptide; 2. Development of the Photoactivatable Prodrugs of Doxazolidine

  2017cites this paper
• Overexpression and enhanced specific activity of aldoketo reductases (AKR1B1 & AKR1B10) in human breast cancers.

  2017cites this paper
• Active targeting of cancer cells using gemcitabine conjugated platinum nanoparticles

  2017cites this paper
• Overexpression of ANLN contributed to poor prognosis of anthracycline-based chemotherapy in breast cancer patients

  2017cites this paper
• Inhibiting autophagy increases epirubicin's cytotoxicity in breast cancer cells

  2016cites this paper
• Preclinical Evaluation of Fatty Acid Synthase and EGFR Inhibition in Triple-Negative Breast Cancer

  2016cites this paper
• Correlation of in Situ Oxazolidine Formation with Highly Synergistic Cytotoxicity and DNA Cross-Linking in Cancer Cells from Combinations of Doxorubicin and Formaldehyde.

  2016cites this paper
• Didox and resveratrol sensitize colorectal cancer cells to doxorubicin via activating apoptosis and ameliorating P-glycoprotein activity

  2016cites this paper
• Doxorubicin-Loaded Nanobubbles Combined with Extracorporeal Shock Waves: Basis for a New Drug Delivery Tool in Anaplastic Thyroid Cancer

  2016cites this paper
• Gynura procumbens Prevents Chemoresistance through Inhibition MDR1 Expression on MCF-7 Breast Cancer Cell Line and Sensitizes the Cells to Doxorubicin

  2015cites this paper
• Role of p53 Codon72 SNP in breast cancer risk and anthracycline resistance.

  2015cites this paper
• Autophagy facilitates multidrug resistance development through inhibition of apoptosis in breast cancer cells.

  2015cites this paper
• Autophagy facilitates multidrug resistance development through inhibition of apoptosis in breast cancer cells

  2015cites this paper
• Synthesis and Application of the Doxaz-MARCKS Prodrug

  2015cites this paper
• Drug transporters in breast cancer: response to anthracyclines and taxanes

  2015cites this paper
• Proteomic analysis of zoxamide-induced changes in Phytophthora cactorum.

  2014cites this paper
• Experiments and synthesis of bone-targeting epirubicin with the water-soluble macromolecular drug delivery systems of oxidized-dextran

  2014cites this paper
• The regulation of FOXM1 in breast cancer

  2014cites this paper
• Spongean alkaloids protect rat kidney cells against cisplatin-induced cytotoxicity

  2014cites this paper
• Vosaroxin for acute myeloid leukemia

  2014cites this paper
• Activation of Immune-Mediated Tumor Cell Death by Chemotherapy

  2013cites this paper
• Long-term biomonitoring of breast cancer patients under adjuvant chemotherapy: the comet assay as a possible predictive factor.

  2013cites this paper
• Applications of Solid Lipid Nanoparticle in Novel Drug Delivery System

  2013cites this paper
• DECLARATION OF ORIGINALITY

  2013cites this paper
• The association between chemosensitivity and Pgp, GST-π and Topo II expression in gastric cancer

  2013cites this paper
• BRITISH BIOMEDICAL BULLETIN

  2013cites this paper
• Glutathione Transferase (GST)-Activated Prodrugs

  2013cites this paper
• Signaling and Regulation The p 38 MAPK – MK 2 Axis Regulates E 2 F 1 and FOXM 1 Expression after Epirubicin Treatment

  2012cites this paper
• Simultaneous Letrozole Letrozole Letrozole + doxorubicin Letrozole + doxorubicin Letrozole + docetaxel Letrozole + docetaxel Letrozole + doxorubicin + docetaxel Letrozole + doxorubicin + docetaxel Sequential Letrozole Letrozole Letrozole Doxorubicin Letrozole Docetaxel Letrozole Doxorubicin + doceta

  2012cites this paper
• Increased cellular accumulation and distribution of amrubicin contribute to its activity in anthracycline-resistant cancer cells

  2012cites this paper
• Nuclear mapping of nanodrug delivery systems in dynamic cellular environments.

  2012cites this paper
• Development of polymer and lipid based nano-delivery systems for targeted cancer chemotherapy

  2012cites this paper
• Antagonism between curcumin and the topoisomerase II inhibitor etoposide

  2012cites this paper
• Drug-Loaded Lipid Nanoparticles for Improved Cancer Treatment: Engineering, In-Vitro, and In-Vivo Evaluation

  2012cites this paper
• Inhibition of aldehyde dehydrogenase (ALDH) activity reduces chemotherapy and radiation resistance of stem-like ALDHhiCD44+ human breast cancer cells

  2012cites this paper
• Genetic Variations Associated with Resistance to Doxorubicin and Paclitaxel in Breast Cancer

  2012cites this paper
• Mitochondria-targeted Doxorubicin is Active and Resistant to Drug Efflux

  2012cites this paper
• Targeted Prodrugs of a Novel Platform Anthracycline: Doxazolidine

  2012cites this paper
• In vivo controlled release and prolonged antitumor effects of 2-methoxyestradiol solid lipid nanoparticles incorporated into a thermosensitive hydrogel

  2012cites this paper
• Synthesis and biological characterization of protease-activated prodrugs of doxazolidine.

  2012cites this paper
• The aromatase inhibitor letrozole enhances the effect of doxorubicin and docetaxel in an MCF7 cell line model

  2012cites this paper
• The p38 MAPK–MK2 Axis Regulates E2F1 and FOXM1 Expression after Epirubicin Treatment

  2012cites this paper
• Linoleic acid-grafted chitosan oligosaccharide micelles for intracellular drug delivery and reverse drug resistance of tumor cells.

  2011cites this paper
• Development of stealth liposome coencapsulating doxorubicin and fluoxetine

  2011cites this paper
• Modern insights into hepatic arterial infusion for liver metastases from colorectal cancer.

  2011cites this paper
• Signal Transduction Pathways in Breast Cancer – Drug Targets and Challenges

  2011cites this paper
• A Serum Protein Profile Predictive of the Resistance to Neoadjuvant Chemotherapy in Advanced Breast Cancers*

  2011cites this paper
• Alpha-tocopheryl succinate enhances doxorubicin-induced apoptosis in human gastric cancer cells via promotion of doxorubicin influx and suppression of doxorubicin efflux.

  2011cites this paper
• Autophagy protects breast cancer cells from epirubicin-induced apoptosis and facilitates epirubicin-resistance development

  2011cites this paper
• ATM and p53 Regulate FOXM1 Expression via E2F in Breast Cancer Epirubicin Treatment and Resistance

  2011cites this paper
• Investigation of a new injectable thermosensitive hydrogel loading solid lipid nanoparticles.

  2011cites this paper
• MEMBRANE PROTEINS AND PROTEOMICS - UN AMOUR POSSIBLE?

  2011cites this paper
• Pharmacological modulation and manipulation of cancer drug resistance

  2010cites this paper
• Cytotoxicity, intracellular distribution and uptake of doxorubicin and doxorubicin coupled to cell-penetrating peptides in different cell lines: a comparative study.

  2010cites this paper
• Development of methotrexate proline prodrug to overcome resistance by MDA-MB-231 cells.

  2010cites this paper
• Voreloxin, a first-in-class anticancer quinolone derivative, acts synergistically with cytarabine in vitro and induces bone marrow aplasia in vivo

  2010cites this paper
• Immunogenic cell death, DAMPs and anticancer therapeutics: an emerging amalgamation.

  2010cites this paper
• Solid lipid nanoparticles in cancer therapy

  2010cites this paper
• Comparative effects of thermosensitive doxorubicin-containing liposomes and hyperthermia in human and murine tumours

  2010cites this paper
• Chemistry and biology of landomycins, an expanding family of polyketide natural products.

  2009cites this paper
• RATIONAL DRUG DESIGN: AN INFORMATION DRIVEN APPROACH TO THE DESIGN OF AN ANTHRACYCLINE ANALOG

  2009cites this paper
• Paclitaxel-resistance conferred by altered expression of efflux and influx transporters for paclitaxel in the human hepatoma cell line, HepG2.

  2009cites this paper
• Maurocalcine as a Non Toxic Drug Carrier Overcomes Doxorubicin Resistance in the Cancer Cell Line MDA-MB 231

  2009cites this paper
• Development of idarubicin and doxorubicin solid lipid nanoparticles to overcome Pgp-mediated multiple drug resistance in leukemia.

  2009cites this paper
• Expression of Multidrug Resistance-Related Proteins p-Glycoproteinglutathione-s-Transferases, Topoisomerase-II and Lung Resistance Protein in Primary Gastric Cardiac Adenocarcinoma

  2008cites this paper
• Prevention of MDR development in leukemia cells by micelle-forming polymeric surfactant.

  2008cites this paper
• 2-Methoxyestradiol and multidrug resistance: can 2-methoxyestradiol chemosensitize resistant breast cancer cells?

  2008cites this paper
• Expression of multidrug resistance-related proteins p-glycoprotein, glutathione-s-transferases, topoisomerase-II and lung resistance protein in primary gastric cardiac adenocarcinoma.

  2008cites this paper
• Targeting prostate cancer based on signal transduction and cell cycle pathways

  2008cites this paper
• The multifactorial nature of hypoxia-induced drug resistance in cancer: involvement of hypoxia-inducible factor 1

  2008cites this paper
• Quantitative membrane proteomics applying narrow range peptide isoelectric focusing for studies of small cell lung cancer resistance mechanisms

  2008cites this paper
• Sabarubicin.

  2008cites this paper
• A Cannabinoid Anticancer Quinone, HU-331, Is More Potent and Less Cardiotoxic Than Doxorubicin: A Comparative in Vivo Study

  2007cites this paper
• Ongoing phase I and II studies of novel anthracyclines

  2007cites this paper
• Proline prodrug of melphalan, prophalan-L, demonstrates high therapeutic index in a murine melanoma model.

  2007cites this paper
• Rapid and sensitive liquid chromatography-tandem mass spectrometry for the quantitation of epirubicin and identification of metabolites in biological samples.

  2007cites this paper